Adaptive Biotech shareholders elect three Class III directors, approve advisory compensation, ratify auditor

Adaptive Biotechnologies Corp

Chad Robins, Kevin Conroy, Michael Pellini elected as Class III directors to 2025 term.
Advisory vote on 2021 NEO compensation approved: 72.7M for, 44.5M against, 298k abstentions.
Ernst & Young ratified as independent auditor for FY2022: 129.8M for, 55k against, 71k abstentions.
All proposals passed at June 10, 2022 annual meeting; no broker non-votes for auditor ratification.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.